Terbinafine gel - MediQuest Therapeutics

Drug Profile

Terbinafine gel - MediQuest Therapeutics

Alternative Names: IVR-101; MQX-5866; MQX-5867; Organogel - MediQuest Therapeutics; Organogel of terbinafine 2% or 6%

Latest Information Update: 09 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MediQuest Therapeutics
  • Developer Ivrea Pharmaceuticals
  • Class Antifungals; Naphthalenes; Small molecules
  • Mechanism of Action Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Onychomycosis

Most Recent Events

  • 09 Feb 2016 No development reported - Phase-II for Onychomycosis in USA (Topical)
  • 30 May 2013 Biomarkers information updated
  • 28 Aug 2012 Clinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top